The firm expects mid-single-digit price erosion in generic drugs and heightened competition for key medications, potentially ...

Healthcare stocks see mixed performance as Dr Lal Pathlabs and Aurobindo Pharma rise over 2% after CLSA upgrades their ...

CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from INR1,140 to INR1,090 ...

This steady growth in HDFC Bank's core earnings - both NII and net profit - came in despite a marginal rise in NPAs and NPA ...

CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from INR1,140 to INR1,090 ...

CLSA has initiated coverage on Hyundai Motor India with an 'Outperform' rating and a target price of Rs 2,155, citing strong ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 15.45% ...

The brokerage firm has also added Zomato to its high conviction outperform list, saying the recent correction is a buying ...

India's most valued company, Reliance Industries Ltd (RIL), reported a robust performance in the third quarter of the current ...

This is the first time Indus Towers has received a ₹575 target, making it the highest among analysts covering the telecom ...

HCLTech declared a dividend of Rs 18 per share, including a special Rs 6 per share dividend to commemorate 25 years since its ...